Lineage Cell Therapeutics Inc (NYSE American: LCTX) is a clinical-stage biotechnology company that develops cell therapy product candidates for unmet medical needs. Revenue is generated through collaboration and license arrangements, including an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. executed December 17, 2021, under which Lineage recognizes revenue based on performance obligations and costs incurred toward completion. The company has no approved commercial products as of the 10-K filed March 5, 2026, and operates as a smaller reporting company headquartered in Carlsbad, California. Lineage holds interests in subsidiary Cell Cure Neurosciences Ltd, which is party to agreements with Hadasit Medical Research Services and Development Ltd. The company funds operations primarily through equity financings, including securities purchase agreements executed November 19, 2024. All properties are leased. As of the 10-K filing, shares trade on the NYSE American exchange under the ticker LCTX.

Revenue model

Collaboration and license agreements, with revenue recognized under ASC Topic 606 based on performance obligations; an input method measuring costs incurred over total estimated costs determines progress toward completion. The Roche/Genentech collaboration, executed December 17, 2021, is the primary disclosed arrangement.

Products and services

Cell therapy product candidates in clinical development. The filing references human embryonic stem cell (hES cell) based programs. No approved commercial products are disclosed as of the 10-K filed March 5, 2026.

Customers and end markets

Pharmaceutical collaborators, specifically F. Hoffmann-La Roche Ltd and Genentech, Inc. under a December 17, 2021 Collaboration and License Agreement. End markets are not specified beyond cell therapy for unmet medical needs.

Value-chain role

Drug developer and licensor. Lineage conducts research and clinical development and out-licenses rights to larger pharmaceutical partners. It relies on external manufacturing and clinical trial sites and is subject to FDA and foreign regulatory approval processes.

Geographic exposure

Headquarters in Carlsbad, California. Subsidiary Cell Cure Neurosciences Ltd operates under agreements involving Israeli entities (Hadasit Medical Research Services and Development Ltd, HBL-Hadasit Bio-Holdings Ltd). International regulatory requirements are disclosed as applicable to foreign product sales.

Source: SEC 10-K, filed 2026-03-05

Industry: Biological Products, (No Diagnostic Substances) Peers: Fennec Pharmaceuticals Inc Clene Inc Compass Therapeutics Inc. Gritstone bio, Inc. Kronos Bio, Inc. MacroGenics Inc Shuttle Pharmaceuticals Holdings Inc Viking Therapeutics Inc Xoma Royalty Corp